Kymera Therapeutics saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 79.
IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the best-performing stocks often have an RS Rating north of 80 in the early stages of their moves. See if Kymera Therapeutics can continue to rebound and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Kymera Therapeutics is trying to complete a consolidation with a 53.27 entry. See if the stock can break out in volume at least 40% above average.
Kymera Therapeutics showed 0% earnings growth in its most recent report. Sales increased -21%.
Kymera Therapeutics holds the No. 148 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
